Login to Your Account



Merck Serono Gets MS Drug for A Steal from Failed Peptimmune

By Nuala Moran


Tuesday, September 20, 2011
LONDON – Merck Serono SA picked up full rights to the Phase II-ready multiple sclerosis (MS) drug PI-2301 from the wreckage of Peptimmune Inc., for a very modest $1.5 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription